Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO-4D: Rivaroxaban vs Antiplatelet after TAVR
NCT02833948Phase 3Completed
- Sponsor
- ECRI
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of rivaroxaban in Leaflet thrombosis, sponsored by ECRI. Started May 2016; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Leaflet thrombosis
Beyond the preview
Go deeper on NCT02833948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833948.